Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Mild Cognitive Impairment, Cognitive Fun...
Phase NA
Enrollment 60
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate whether binaural beats can improve cognitive function in older adults with mild cognitive impairment living in nursing homes. Participants will listen to 10-Hz alpha-frequency binaural beats through headphones once daily for 30 minutes for 14 consecutive days. Cognitive function, sleep quality, anxiety, and depressive symptoms will be assessed before the intervention, after the intervention, and at a 2-week follow-up after the intervention. The study aims to determine whether binaural beats are a safe, simple, and non-drug approach to support cognitive health in older adults with mild cognitive impairment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Binaural Beats Embedded in Old Songs — Participants in the intervention group will listen to old songs embedded with 10-Hz alpha-frequency binaural beats through headphones once daily for 30 minutes for 14 consecutive days. The old songs will be selected according to older adults' music preferences.
  • Behavioral: Old Songs — Participants in the control group will listen to old songs without binaural beats through headphones once daily for 30 minutes for 14 consecutive days. The old songs will be selected according to older adults' music preferences.

Primary Outcomes

  • Change in Montreal Cognitive Assessment Score (Baseline, immediately after the 14-day intervention, and 2 weeks after the intervention)
  • Change in Digit Span Test Score (Baseline, immediately after the 14-day intervention, and 2 weeks after the intervention)
  • Change in Stroop Color-Word Test Score (Baseline, immediately after the 14-day intervention, and 2 weeks after the intervention)
  • Change in Trail Making Test Score (Baseline, immediately after the 14-day intervention, and 2 weeks after the intervention)
  • Change in Pittsburgh Sleep Quality Index Score (Baseline, immediately after the 14-day intervention, and 2 weeks after the intervention)
  • Change in Geriatric Anxiety Scale Score (Baseline, immediately after the 14-day intervention, and 2 weeks after the intervention)
  • Change in Geriatric Depression Scale-15 Score (Baseline, immediately after the 14-day intervention, and 2 weeks after the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-15
Completion: 2026-09-20
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: China Medical University, China
Contact Information
Study Contact:
Liu Yu Yu Liu, Professor
+8618640068209
liuyu@cmu.edu.cn
Yuhan Geng
18018945883
gengyuhan@cmu.edu.cn
Jintaiyang Jingguan Elderly Care Apartment
Yuhan Geng
18018945883
gengyuhan@cmu.edu.cn
Jintaiyang Elderly Care Center, Huanggu Branch
Interventions
  • Behavioral: Binaural Beats Embedded in Old Songs — Participants in the intervention group will listen to old songs embedded with 10-Hz alpha-frequency binaural beats through headphones once daily for 30 minutes for 14 consecutive days. The old songs will be selected according to older adults' music preferences.
  • Behavioral: Old Songs — Participants in the control group will listen to old songs without binaural beats through headphones once daily for 30 minutes for 14 consecutive days. The old songs will be selected according to older adults' music preferences.
Study Locations (3 sites)
Jintaiyang Jingguan Elderly Care Apartment, Shenyang, Liaoning 110030 China
Jintaiyang Elderly Care Center, Huanggu Branch, Shenyang, Liaoning 110031 China
Renai Changwan Elderly Care Home, Dadong District, Shenyang, Liaoning 110042 China
Eligibility Criteria
Inclusion Criteria: 1. Age 60 years or older. 2. Not previously diagnosed with dementia. 3. Meets the diagnostic criteria for mild cognitive impairment, with Montreal Cognitive Assessment scores adjusted by education level, Mini-Mental State Examination score \>= 24, and Activities of Daily Living score \< 23. 4. Has lived in a nursing home for more than 2 months and plans to continue living there during the study period. 5. No hearing impairment; Hearing Handicap Inventory for the Elderly-Screening Version score \< 8, and able to hear binaural beats through both ears. 6. Conscious and able to cooperate with questionnaires and scale assessments. 7. Has not taken medications that may affect cognitive function within 3 to 6 months before the intervention. Exclusion Criteria: 1. Severe physical disease, major organ failure, or advanced malignant tumor. 2. Diagnosed depression or other psychiatric disorders. Withdrawal Criteria: 1. Serious adverse events during the study, such as falls, disease recurrence, discomfort caused by the intervention audio, death, or other conditions making continued participation unsuitable. 2. Voluntary withdrawal from the study. Removal Criteria: 1. Incomplete data resulting in missing information. 2. Missing three or more intervention sessions within 2 weeks without following intervention instructions. 3. Receiving other treatments or interventions related to cognitive function during the trial.
Conditions Hypoxia, Mental Disorder
Phase NA
Enrollment 68
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Introduction: Currently, there is a lack of international guidelines or clinical recommendations for individuals with mental illnesses (i.e., bipolar disorder, posttraumatic stress disorder) going on high altitude sojourns. However, these guidelines would be important considering that mental illnesses are among the most common disorders worldwide and millions of people are hiking at high altitudes in the Alps, being granted easy access up to 3800m by cable cars. Before conceptualizing these guidelines, it seems necessary to study the physiological and psychological effects of ambient pressure changes leading to oxygen deficiency (hypoxia) in individuals with mental illnesses when being exposed to hypoxic conditions. The investigators hypothesize a shift towards negative affective responses and state anxiety as well as increased levels of neurotransmitter precursor amino acids (PHE/TYR and KYN/TRP) in individuals with mental illnesses when being exposed to hypoxic conditions. Methods and Analysis: The investigators plan to perform a double-blind randomized controlled trial in a safe laboratory environment by using a normobaric hypoxic chamber. Participants suffering from depression and anxiety symptoms will be included as well as age and sex-matched healthy controls. They will attend a six-hour exposure equivalent to 3800m of altitude as well as a six-hour exposure to sham hypoxic conditions. Recruited participants will be screened by the Beck Anxiety and Depression Inventory, the Symptom Checklist (SCL-90) as well as an interview assessment. Affective responses in state anxiety will be assessed before, and during each hour of exposure by using the Feeling Scale (FS), Felt Arousal Scale (FAS), Positive and Negative Affect Schedule (PANAS), State-Anxiety Inventory (STAI) and subjective mental stress levels (Visual Analogue Scale; VAS). Physiological parameters will be assessed by venous blood sampling, pulse oximetry and oxidative stress level measurement before entering the chamber, after three and six hours of exposure. Additionally, symptoms of acute mountain sickness will be assessed by the Lake Louise Score before, after three and six hours of exposure. Follow-up measurements are planned one and seven days after the chamber visit, consisting of venous blood sampling, the Beck Anxiety and Depression Inventory. A series of univariate analyses of covariance (ANCOVA) for repeated measures will be used to test the three-way (i.e. "group × condition × time") and two-way ("group × condition" and "group × time") interactions. Analyses will be adjusted for possible confounding, by adding age, sex, smoking, prior AMS, and medication status in the models as covariates. Ethics and dissemination: Ethical approval has been obtained from the ethics committee of the Medical University of Innsbruck (1250/2021).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Biological: Hypoxia — Participants will be randomly assigned to start with the normobaric hypoxia condition or the sham hypoxia condition. They will swap to the other condition during the second visit, which will be executed at least 14 days after the first visit. Each sojourn will last for six hours and participants will reside in the chamber individually. During the six-hour stay, participants will be allowed to move freely within the chamber.

Primary Outcomes

  • Changes in affective responses (up to 6 hours, including 8 measurements, measuring before the start of intervention, every hour during the intervention, and after the end of intervention)
  • Changes in state anxiety (up to 6 hours, including 8 measurements, measuring before the start of intervention, every hour during the intervention, and after the end of intervention)
  • Changes in subjective perception of stress (up to 6 hours, including 8 measurements, measuring before the start of intervention, every hour during the intervention, and after the end of intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-04-14
Completion: 2025-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 68 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitaet Innsbruck
Collaborators: Medical University Innsbruck
Contact Information
Study Contact:
Linda Rausch, PhD
+4351250745851
linda.rausch@uibk.ac.at
University of Innsbruck, Department of Sport Science
Interventions
  • Biological: Hypoxia — Participants will be randomly assigned to start with the normobaric hypoxia condition or the sham hypoxia condition. They will swap to the other condition during the second visit, which will be executed at least 14 days after the first visit. Each sojourn will last for six hours and participants will reside in the chamber individually. During the six-hour stay, participants will be allowed to move freely within the chamber.
Study Locations (1 sites)
University of Innsbruck, Department of Sport Science, Innsbruck, Tyrol 6020 Austria
Eligibility Criteria
Inclusion Criteria: * sufficient command of the German language * no psychotic or cognitive disorders * patients suffering from anxious-depressive symptoms (meeting the cut off points of light-medium in the screening for anxiety and depression symptoms) Exclusion Criteria: * pregnant or breastfeeding * permanent residence above 1000m * overnight stays at altitudes above 2500m in the previous month * exposure to 2500m or higher two weeks prior to the six-hour hypoxic exposure
Conditions Trauma Injury, Depression, Anxiety, Ange...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Animal assisted therapy (AAT) with dogs has been shown to be beneficial for a wide range of patients with both acute and chronic illnesses, including spinal cord injuries, heart failure, myocardial infarctions, strokes, cancer, post-traumatic stress disorder, and depression. Studies have also demonstrated that even in healthy adults, the presence of dogs is associated with physiologic changes such as increased pain threshold, decreased blood pressure, and decreased heart rate. However, few studies have investigated the role of AAT in the post-operative course in adults. This study will investigate the impact of therapy dog visits on pain and anxiety scores for trauma patients at Boston Medical Center (BMC).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Therapy dog visits — 2-3 ten-minute visits by a trained therapy dog and the dog's handler
  • Other: Dog handler visits — 2-3 ten-minute visits by a dog handler

Primary Outcomes

  • Participants' pain assessed with a numeric analog score (24 hours after the last study visit)
  • Participants' pain assessed with pictures of facial expressions (24 hours after the last study visit)
  • Depression assessed by the Brief Mood Survey (24 hours after the last study visit)
  • Anxiety assessed by the Brief Mood Survey (24 hours after the last study visit)
  • Anger assessed by the Brief Mood Survey (24 hours after the last study visit)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-04
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Boston Medical Center
Collaborators: Boston Medical Center Healing Pups Program
Principal Investigators:
  • Sabrina Sanchez, MD MPH (PRINCIPAL_INVESTIGATOR) - Boston Medical Center
Contact Information
Study Contact:
Sabrina Sanchez, MD MPH
617 414 4861
sabrina.sanchez@bmc.org
Sara Myers, MD
617 638 9191
sara.myers@bmc.org
Sabrina Sanchez, MD MPH
617-414-4861
sabrina.sanchez@bmc.org
Boston Medical Center, Trauma Inpatient Service
Interventions
  • Other: Therapy dog visits — 2-3 ten-minute visits by a trained therapy dog and the dog's handler
  • Other: Dog handler visits — 2-3 ten-minute visits by a dog handler
Study Locations (1 sites)
Boston Medical Center, Trauma Inpatient Service, Boston, Massachusetts 02118 United States
Eligibility Criteria
Inclusion Criteria: * Patients admitted to the Trauma and Acute Care Surgery (TACS) service following a trauma * English or Spanish speaking * Able to provide informed consent Exclusion Criteria: * Fear of dogs, allergy to dogs * Immunocompromised * Contact precautions * Delirious, intubated, or otherwise unable to consent
Conditions Traumatic Brain Injury, Insomnia, Depres...
Phase NA
Enrollment 360
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective two-arm, single blind randomized controlled trial design to compare the clinical effectiveness of telemedicine-delivered, 6-session, standardized cognitive behavioral therapy for insomnia (CBT-I) and mindfulness-based treatment for insomnia (MBTI) in treating insomnia symptoms and ameliorating depressive symptoms in persons with mild to moderate TBI and comorbid Post-Traumatic Stress Symptoms (PTSS) and insomnia symptoms in a 360 patients. Participants will undergo assessment (psychosocial questionnaires, neurocognitive testing, sleep monitoring) at baseline, at the end of treatment, and at 2-, 6- and 12-weeks post-treatment. The primary outcome is sleep as measured by the Insomnia Severity Index (ISI).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Mindfulness-based treatment for insomnia (MBTI) — A 6-week intervention that uses the principles and practices of mindfulness meditation along with behavioral strategies (stimulus control, sleep restriction therapy) to reduce symptoms of insomnia
  • Behavioral: Cognitive behavioral therapy for insomnia (CBT-I) — Standard of care for adults with chronic insomnia. 6-week program that uses behavioral techniques to decrease psychophysiological arousal and increase sleep propensity to deepen and consolidate sleep.

Primary Outcomes

  • Change in Insomnia severity as assessed by the insomnia severity index (ISI) (At the end of treatment, and 2-, 6- and 12-weeks post treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-10
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 360 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Collaborators: Congressionally Directed Medical Research Programs
Principal Investigators:
  • Luis Buenaver, PhD (PRINCIPAL_INVESTIGATOR) - Johns Hopkins School of Medicine
Contact Information
Study Contact:
Luis Buenaver, PHD
4105507986
lbuenav1@jhmi.edu
Elizabeth Wysocki, MS
ewysock2@jhu.edu
Mary Fergus
240-204-1573
Intrepid Spirit Center - Eglin Air Force Base
Interventions
  • Behavioral: Mindfulness-based treatment for insomnia (MBTI) — A 6-week intervention that uses the principles and practices of mindfulness meditation along with behavioral strategies (stimulus control, sleep restriction therapy) to reduce symptoms of insomnia
  • Behavioral: Cognitive behavioral therapy for insomnia (CBT-I) — Standard of care for adults with chronic insomnia. 6-week program that uses behavioral techniques to decrease psychophysiological arousal and increase sleep propensity to deepen and consolidate sleep.
Study Locations (5 sites)
Intrepid Spirit Center - Eglin Air Force Base, Eglin Air Force Base, Florida 32542 United States
Naval School Explosive Ordance Disposal - Eglin Air Force Base, Eglin Air Force Base, Florida 32542 United States
Walter Reed National Medical Military Center, Bethesda, Maryland 20814 United States
Womack Army Medical Center, Fort Bragg, North Carolina 28310 United States
Madigan Army Medical Center, Fort Lewis, Washington 98431 United States
Eligibility Criteria
Inclusion Criteria: 1. Current or former member of the uniform services 2. Meet the Veterans Affairs Medical Center (VAMC) Department of Defense (DoD) criteria for TBI; 3. Time duration since traumatic brain injury (TBI) injury \>90 days 4. Insomnia symptom duration \>90 days 5. Endorse insomnia symptoms (Insomnia Severity Index \[ISI\] score \> 10) 6. Display sufficient cognitive capacity to provide informed consent (Montreal Cognitive Assessment (MoCA) Z-score \> -2) 7. \>18 years of age 8. Access to and ability and to use computer. Exclusion Criteria: 1. History of neurological diseases other than TBI and not attributable to TBI 2. Sleep apnea \[apnea hypopnea index (AHI) \>15; individuals with mild apnea (AHI \> 5 and \<15) will be informed, but allowed to participate\]. Participants who use a continuous positive airway pressure (CPAP) device for sleep apnea will be eligible for participation if they are below the apnea/hypopnea cutoff while using CPAP, are adherent to using the device (\> 4 hours/night 21/30 consecutive days) and agree to continue using the device during study participation. 3. Lastly, people using psychotropic medications may be included if they are on a stable dosage for the last three weeks prior to the study.

Biobank and Brain Health in Bordeaux.

NCT05322343
Recruiting
Conditions Brain, Aging, Cognitive Aging, Immunosen...
Phase Not Applicable
Enrollment 2050
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

B cube is a new generation cohort to study the determinants and natural history of brain aging, using molecular epidemiology, in a representative sample (N=2000) of the general population from the age of 55 (the approximate age of onset of the first cognitive disorders and a target population particularly receptive to prevention messages). Special interest will be given to nutrition, a promising environmental exposure for prevention.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Questionnaires — Participants will complete a series of three questionnaires at the V1 (at home, by a trained interviewer) repeated at V7 for the follow up phase: 1. A general questionnaire, with collection of general health history and exposure data 2. A nutritional survey (24-hour recall), that will be repeated by telephone twice at 3-month intervals, at the V4 and V5, V6 visits. and V7, V9, V10 et V11 for the follow-up phase 3. An evaluation of cognitive performance using a validated computerized battery (Cantab®), completed of neuropsychological tests to evaluate dementia syndromes, depressive symptoms and anxiety.
  • Other: Fasting blood sampling. — In the morning, during the V2 visit by a nurse at the participant's home. Blood collection will include 8 blood tubes (volume approx.. 35.5 mL), plus 2 additional tubes for 500 participants accepting MRI, for a total volume of blood drawn of 41.5 mL for these participants. For the immunological substudy, a second sample will be taken at a distance (after 4 weeks) for 150 volunteer participants meeting the criteria. The blood collection is repeated at V8 during the follow-up phase (21 mL).
  • Other: Saliva collection and nasal or nasopharyngeal swab — On the day of the V2 visit, the nurse will collect a volume of saliva that has flowed spontaneously for 5 min in a sterile 40-mL polypropylene tube, and a nasal or nasopharyngeal swab using a specific kit.
  • Other: Urine and stool samples — During the V2 visit, the nurse will collect urine and stool samples collected by the participant in the week preceding the appointment, using the equipment provided and kept in the refrigerator. Stool sampling os repeated at V8 during the follow-up phase.
  • Other: Hair and a tonenail (or hand nail) sampling — During the V2 visit, the nurse will collect some hair and a toenail sample from the participant, in a dedicated envelope. The hair collection is repeated at V8 during the follow-up phase.
  • Other: Nasal microbiota — Nasal or nasopharyngeal swab
  • Other: Measurements — In addition to the samples, anthropometric measurements (weight, height,ead, waist, hip, calf and arm circumferences, subjective evaluation of body shape trajectories over the lifecourse), blood pressure, orthostatic hypotension, walking speed, grip strength, and hearing screening of sarcopenia and Parkinson's syndromes will also be collected by the nurse on the day of the V2 visit. Some of these measures (blood pressure, grip strength, screening of sarcopenia and Parkinson's syndromes) are repeated at V8 during the follow-up visit. Analyses may be performed on the biobank samples. These analyses will include metabolite assays (Metabolon®), and may include genotyping for research purposes (without searching for specific genes.
  • Other: Neuroimaging — A multi-sequence MRI will be performed at the V3 visit. None of the sequences used will require contrast injection. The MRI sequences used will be: a 3D MPRAGE T1-weighted sequence, a T2-weighted sequence (FLAIR), a diffusion EPI sequence, a magnetization transfer sequence, and a resting state functional MRI BOLD sequence. The total duration of the MRI examination will be approximately 50 minutes. The MRI will be performed at the Bioimaging Institute on an imager dedicated to research activities (3T Prisma Siemens).During V3 visit, a measurement of skin autofluorescence of advanced glycation products will also be performed

Primary Outcomes

  • Number of participants for whom samples are available in the biobank and nutritional and cognitive surveys have been completed. (Inclusion visit)
  • Number of participants for whom samples are available in the biobank and nutritional and cognitive surveys have been completed. (week 1)
  • Number of participants for whom samples are available in the biobank and nutritional and cognitive surveys have been completed. (week 2)
  • Number of participants for whom samples are available in the biobank and nutritional and cognitive surveys have been completed. (week 12 and week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-03-22
Completion: 2030-03-22
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: true
Enrollment: 2050 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Bordeaux
Principal Investigators:
  • Cécilia SAMIERI, Dr (PRINCIPAL_INVESTIGATOR) - Bordeaux Population Health Researh Center Inserm
Contact Information
Study Contact:
Cécilia SAMIERI, Dr
5 57 57 45 15
cecilia.samieri@u-bordeaux.fr
SAMIERI Cécilia, Dr
05 57 57 45 15
cecilia.samieri@u-bordeaux.fr
University Hospital of Bordeaux
Interventions
  • Other: Questionnaires — Participants will complete a series of three questionnaires at the V1 (at home, by a trained interviewer) repeated at V7 for the follow up phase: 1. A general questionnaire, with collection of general health history and exposure data 2. A nutritional survey (24-hour recall), that will be repeated by telephone twice at 3-month intervals, at the V4 and V5, V6 visits. and V7, V9, V10 et V11 for the follow-up phase 3. An evaluation of cognitive performance using a validated computerized battery (Cantab®), completed of neuropsychological tests to evaluate dementia syndromes, depressive symptoms and anxiety.
  • Other: Fasting blood sampling. — In the morning, during the V2 visit by a nurse at the participant's home. Blood collection will include 8 blood tubes (volume approx.. 35.5 mL), plus 2 additional tubes for 500 participants accepting MRI, for a total volume of blood drawn of 41.5 mL for these participants. For the immunological substudy, a second sample will be taken at a distance (after 4 weeks) for 150 volunteer participants meeting the criteria. The blood collection is repeated at V8 during the follow-up phase (21 mL).
  • Other: Saliva collection and nasal or nasopharyngeal swab — On the day of the V2 visit, the nurse will collect a volume of saliva that has flowed spontaneously for 5 min in a sterile 40-mL polypropylene tube, and a nasal or nasopharyngeal swab using a specific kit.
  • Other: Urine and stool samples — During the V2 visit, the nurse will collect urine and stool samples collected by the participant in the week preceding the appointment, using the equipment provided and kept in the refrigerator. Stool sampling os repeated at V8 during the follow-up phase.
  • Other: Hair and a tonenail (or hand nail) sampling — During the V2 visit, the nurse will collect some hair and a toenail sample from the participant, in a dedicated envelope. The hair collection is repeated at V8 during the follow-up phase.
Study Locations (1 sites)
University Hospital of Bordeaux, Bordeaux, Bordeaux 33300 France
Eligibility Criteria
Inclusion Criteria: For the main study: 1. live in Bordeaux metropolitan area, 2. be between 55 and 80 years old (included), 3. selected in terms of socioeconomic level, according to a sampling strategy by age groups and income categories representative of the general population between 55 and 80 years of age 4. be affiliated with the social security system, 5. agree to take a blood sample for the biobank. For the MRI sub-study: be between 55 and 75 years old (included). Inclusion criteria for the immune response substudy: be 70 years of age or older or participate in the MRI study; agree to take a supplemental blood sample for this substudy. Exclusion Criteria: For the main study: persons under guardianship (or more generally under protection), unable to give consent to participate. For the MRI sub-study: have a contraindication to MRI examination (pacemaker, a valve prosthesis or any other internal electrical/magnetic device; history of neurosurgery or aneurysm; claustrophobia; presence of metal fragments in the eyes, brain or spinal cord).
Conditions Hypertension, Hypertrophy
Phase PHASE1
Enrollment 112
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The prevalence of congestive heart failure (CHF) in Canada is high, representing one of the health care system's most expensive diagnoses. Despite major advances in medicine, the mortality and morbidity from CHF remains great. Currently, magnetic resonance imaging (MRI) is used for non-invasive imaging of the cardiovascular system to enable the structure and anatomy of the organ to be visualized. However, current MRI methods have limitations when assessing and aiding in the management of CHF. A new imaging method has recently been developed that is showing great promise as a tool in the management of patients with CHF. Rapid imaging of biochemical reactions within myocytes using MRI has recently become possible through the use of the Dynamic Nuclear Polarization (DNP) and dissolution method. DNP-dissolution results in an intravenous contrast agent that is "hyperpolarized", producing a magnetic signal that is enhanced by up to 100,000 fold. The particular agent is carbon-13 labelled pyruvate. In this study, we demonstrate the first 13C-metabolic images of the human heart, along with the required hardware and data acquisition methods.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Drug: Hyperpolarized (13) Pyruvate Injection — MRI with Hyperpolarized Pyruvate (13) Injection
  • Drug: Gadolinium — MRI with Gadolinium

Primary Outcomes

  • Ability of the MRI machine to produce an image of the participant's heart following an injection of Hyperpolarized Pyruvate (13C) as assessed by the physician (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2016-04
Completion: 2027-04
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: true
Enrollment: 112 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sunnybrook Health Sciences Centre
Principal Investigators:
  • Charles Cunningham, PhD (PRINCIPAL_INVESTIGATOR) - Sunnybrook Research Institute
Contact Information
Study Contact:
Norberto Garcia
4164806100
norberto.garcia@sunnybrook.ca
Norberto Garcia
4164806100
norberto.garcia@sunnybrook.ca
Sunnybrook Health Sciences Centre
Charles Cunningham, PhD
Sunnybrook Health Sciences Centre
Interventions
  • Drug: Hyperpolarized (13) Pyruvate Injection — MRI with Hyperpolarized Pyruvate (13) Injection
  • Drug: Gadolinium — MRI with Gadolinium
Study Locations (2 sites)
Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5 Canada
St. Michael's Hospital, Toronto, Ontario Canada
Eligibility Criteria
Inclusion Criteria * Written consent * Age: 19 to 50 in Arm 1, 30 to 75 in Arm 2 * Group 2A and 2E participants have left-ventricular hypertrophy * Group 2B and 2F participants have diagnosed hypertrophic cardiomyopathy * Group 2C and 2G participants are stable outpatients with NYHA class 1-3 heart failure with evidence of elevated LV mass (LVH), irrespective of LVEF. * Group 2D and 2H participants are stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents Exclusion Criteria * Contraindications to MRI or MRI contrast agents * Hemoglobin ≤ 9.0 gm/dL (only Group 2 participants) * Glomerular filtration rate (based on MDRD Equation) \< 30 ml/min/1.73m2 (only Group 2 participants) * Any condition leading to a life expectancy \<1 year * Medically diagnosed claustrophobia * Have received, or are scheduled to receive, another investigational medicinal product from 1 month prior to 1 month after inclusion in this study * BMI of less than 18.5 or greater than 32 * Group 1: medically diagnosed heart disease
Conditions Cirrhosis, Splenectomy, Portal Vein Thro...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy and azygoportal disconnection.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Apixaban 2.5 MG — If portal vein thrombosis occurs more than one year after laparoscopic splenectomy and azygoportal disconnection, the patient will orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily. Then, Doppler ultrasound screening or contrast-enhanced CT scans will be used to evaluate the changes in portal vein thrombosis after apixaban treatment. If it is effective, patients will take apixaban all the time.

Primary Outcomes

  • Proportion of complete recanalization of portal vein thrombosis (Follow-up of 6 months or greater)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-01
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Northern Jiangsu People's Hospital
Principal Investigators:
  • Dou-Sheng Bai (STUDY_CHAIR) - Clinical Medical College, Yangzhou University
Contact Information
Study Contact:
Guo-Qing Jiang, MD
+8651487373272
jgqing2003@hotmail.com
Dou-Sheng Bai, MD
+8651487373275
bdsno1@hotmail.com
Guo-Qing Jiang, MD
+8651487373382
jgqing2003@hotmail.com
Clinical Medical College
Interventions
  • Drug: Apixaban 2.5 MG — If portal vein thrombosis occurs more than one year after laparoscopic splenectomy and azygoportal disconnection, the patient will orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily. Then, Doppler ultrasound screening or contrast-enhanced CT scans will be used to evaluate the changes in portal vein thrombosis after apixaban treatment. If it is effective, patients will take apixaban all the time.
Study Locations (1 sites)
Clinical Medical College, Yangzhou, Jiangsu 225001 China
Eligibility Criteria
Inclusion Criteria: 1. A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology. 2. Portal hypertension bleeding . 3. Splenomegaly with secondary hypersplenism. 4. No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery. 5. Underwent laparoscopic splenectomy at our center. 6. Orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily or a 100 mg aspirin tablet (Bayer, Leverkusen, Germany) once daily for 6 months from POD 3. 7. subcutaneous injections of low molecular weight heparin sodium (CSBio, Hebei, China) were administered for 5 days from POD 3 8. Oral dipyridamole (Henan Furen, Henan, China) at a dosage of 25 mg, administered three times daily for 3 months from POD 3. 9. Had no imaging evidence (Doppler ultrasound or CT) of portal vein thrombosis during postoperative months 6 to 12. 10. Developed portal vein thrombosis after 12 months post-surgery. 11. Provided informed consent to participate in the study. Exclusion Criteria: 1. Hepatocellular carcinoma or any other malignancy. 2. Hypercoagulable state other than the liver disease related. 3. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs. 4. Child - Pugh C 5. Recent peptic ulcer disease 6. History of Hemorrhagic stroke 7. Pregnancy. 8. Uncontrolled Hypertension 9. Human immunodeficiency virus (HIV) infection
Conditions Hypertension
Phase PHASE1
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: IBI3016 Dose 4 — single doses of IBI3016 administered by subcutaneous injection
  • Drug: IBI3016 Dose 3 — single doses of IBI3016 administered by subcutaneous injection
  • Drug: IBI3016 Dose 2 — single doses of IBI3016 administered by subcutaneous injection
  • Drug: IBI3016 Dose 1 — single doses of IBI3016 administered by subcutaneous injection
  • Drug: Placebo — single doses of IBI3016 administered by subcutaneous injection

Primary Outcomes

  • Number of Participants with Adverse Events (Through 24 weeks, up to approximately 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-08-01
Completion: 2027-11-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Contact Information
Study Contact:
Wendy Duan
+86 010-87412310
wenjing.duan@innoventbio.com
Congying Xia
congying.xia@innoventbio.com
Kotaro Tsushima
+81-6-6395-9000
ophach_chiken@heishinkai.com
Medical Corporation Heishinkai OPHAC Hospital
Interventions
  • Drug: IBI3016 Dose 4 — single doses of IBI3016 administered by subcutaneous injection
  • Drug: IBI3016 Dose 3 — single doses of IBI3016 administered by subcutaneous injection
  • Drug: IBI3016 Dose 2 — single doses of IBI3016 administered by subcutaneous injection
  • Drug: IBI3016 Dose 1 — single doses of IBI3016 administered by subcutaneous injection
  • Drug: Placebo — single doses of IBI3016 administered by subcutaneous injection
Study Locations (1 sites)
Medical Corporation Heishinkai OPHAC Hospital, Osaka, 532-003 Japan
Eligibility Criteria
Inclusion Criteria: * 1\. Male or female participants aged 18-75 years (inclusive) at the time of informed consent; * 2\. Must have been born in Japan, and their biological parents and grandparents must have been of Japanese origin; * 3\. Office mean sitting SBP≥ 140 mmHg and \< 170 mmHg at screening Exclusion Criteria: * 1\. Participants with secondary hypertension, including but not limited to the following conditions: obstructive sleep apnea; * 2\. History of orthostatic hypotension * 3\. Current or history of intolerance to AECI, ARB, ARNI or direct renin inhibitor * 4\. With diseases that require treatment with renin-angiotensin-aldosterone system (RAAS) inhibitors other than hypertension at screening; * 5\. Presence of serious active and uncontrolled physical conditions or medical history, which may be in a dangerous state during the use of the study drug, or interfere with the interpretation of efficacy and safety data of this study, as judged by the investigator prior to randomization
Conditions Renal Artery Stenosis Atherosclerotic, S...
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Although randomized trials have demonstrated there is no benefit of renal-artery stenting in addition to medical therapy for patients with atherosclerosis renal artery stenosis, many patients indeed gained benefit in daily practices after stenting, such as reduction in blood pressure and recovery in renal functions. One important gap is that there is no universal standard to determine whether to stent in these patients. Fraction Flow Reserve (FFR) has been studied for many year in chronic coronary heart disease and FFR-guided revascularization strategy is known to be better than both angiography-guided revascularization and medication alone. Based on the primary finding of FAIR-pilot study (NCT05732077), FFR-guided renal artery stenting is practical. The overall purpose of the FAIR trial is to compare the clinical outcomes and safety of FFR-guided stenting plus optimal medical treatment (OMT) versus OMT alone in patients with renal-vascular hypertensive patients. With the 'all comers' design, participants met the inclusive/exclusive criteria will be enrolled, and hyperemic FFR induced by dopamine will be measured in all participants. If FFR is ≥0.80, patients will be treated with OMT alone and follow up. If FFR is \<0.80, participants will be randomized to stenting in the renal artery plus OMT or OMT alone on a 1:1 ratio. The blood pressure and anti-hypertensive medications will be compared before and 3 months after the procedure based on ambulatory blood pressure monitoring, all participants will be followed up for 1 year.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Dopamine — A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
  • Diagnostic Test: Fractional Flow Reserve, Renal — Renal FFR will be measured based on SOP
  • Device: Renal artery stenting — Renal artery stenting will be implanted based on the protocol

Primary Outcomes

  • Change in daytime mean systolic blood pressure as measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM) (From baseline to 3 months post-procedure)
  • Change in the composite index of antihypertensive drugs (From baseline to 3 months post-procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-03
Completion: 2027-04-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University First Hospital
Contact Information
Study Contact:
Yuxi Li, MD
00861083572283
liyuxi@pku.edu.cn
Yuxi Li, MD
00861083572283
liyuxi@pku.edu.cn
Peking University First Hospital
Jianping Li, MD
Peking University First Hospital
Interventions
  • Drug: Dopamine — A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
  • Diagnostic Test: Fractional Flow Reserve, Renal — Renal FFR will be measured based on SOP
  • Device: Renal artery stenting — Renal artery stenting will be implanted based on the protocol
Study Locations (1 sites)
Peking University First Hospital, Beijing, Beijing Municipality 100034 China
Eligibility Criteria
Inclusion Criteria: * With recorded hypertension, AND the blood pressure is not controlled (daytime mean SBP ≥135 mmHg and/or DBP ≥85 mmHg based on ABPM) on 2 or more classes of anti-hypertensive drugs; * Evidence of renal artery stenosis and undergoing renal artery angiography; * Able to follow the study protocol and provide informed consent; * Renal artery angiography shows at least 1 main artery with stenosis of 50%-90%, AND the diameter is ≥ 4.0mm. Exclusion Criteria: * SBP ≥200mmHg and/or DBP ≥120mmHg at the day or randomization; * Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis; * Pregnancy or unknown pregnancy status in female of childbearing potential; * Participation in any drug or device trial during the study period; * Any stroke/TIA, OR with ≥70% stenosis of carotid artery; * Any major surgery, myocardial infarction or interventional therapy 30 days prior to study entry; * LVEF \<30%; * Comorbidity condition causing life expectancy ≤1 year; * Allergy to contrast or any of the following: aspirin, clopidogrel; * Previous kidney transplant; * Previous renal artery bypass surgery or stent intervention; * Kidney size less than 8 cm measured by ultrasound; * Local lab serum Cr \>3.0 mg/dl (265.2μmol/l) on the day of randomization; * Reference vessel size \<4 mm or \>8 mm.
Conditions Primary Aldosteronism, Hypertension
Phase Not Applicable
Enrollment 240
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn whether screening for primary aldosteronism can be improved among patients on chronic blood pressure-lowering medications by ordering intake of 1 mg of dexamethasone prior to hormonal examinations. Primary aldosteronism is a condition, in which an adrenal gland steroid aldosterone is released in excessive amounts; it commonly causes hypertension but requires specific therapy different from usually prescribed in other forms of hypertension. Dexamethasone is a synthetic steroid used for both therapeutic and diagnostic purposes. A single 1 mg dexamethasone dose taken at 11 p.m. in order to measure hormone concentrations the following morning (so called overnight 1-mg dexamethasone test) is a commonly applied test in the work-up of adrenal disorders. The main question the project aims to answer is: Can screening for primary aldosteronism be improved among patients receiving blood pressure-lowering medications with overnight 1-mg dexamethasone intake? Participants will undergo changes in their chronic medication to be able to definitely rule out or confirm primary aldosteronism in blood hormonal examinations. These modifications and modifications are not part of the research project. For this project participants will be asked to * undergo the 1-mg dexamethasone test one to three times in order to compare hormonal concentrations before and after it, * collect urine for 24 hours to determine aldosterone in the urine sample after medications interfering in aldosterone release are temporarily withdrawn.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Primary Outcomes

  • Overall diagnostic accuracy of post-DXM ARR (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-22
Completion: 2026-10-31
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Gdansk
Principal Investigators:
  • Piotr Kmiec, MD, Ph.D. (PRINCIPAL_INVESTIGATOR) - Department of Endocrinology and Internal Medicine, Medical University of Gdansk
Contact Information
Study Contact:
Piotr Kmiec, M.D., Ph.D.
0048 585844809
piotrkmiec@gumed.edu.pl
Renata Swiatkowska-Stodulska, Professor, MD, Ph.D.
0049 585844800
rensto@gumed.edu.pl
Piotr Kmiec, MD, Ph.D.
0048 585844809
piotrkmiec@gumed.edu.pl
Department of Endocrinology and Internal Medicine, University Clinical Center, Medical University of Gdansk
Interventions
N/A
Study Locations (1 sites)
Department of Endocrinology and Internal Medicine, University Clinical Center, Medical University of Gdansk, Gdansk, Pomeranian Voivodeship 80214 Poland
Eligibility Criteria
Inclusion Criteria: * suspected or diagnosed HT, * age between 40 and 75, * available aldosterone and renin result at the time of one-day clinic stay, * scheduled 1-mg-DXM test (indicated for possible mild autonomous cortisol secretion, MACS), * presence of an adrenal lesion with radiologic features of adrenocortical adenoma/hyperplasia. Exclusion Criteria: * baseline (pre-DXM) hyperreninemia (renin exceeding the upper limit of normal at the study site, i.e. 46.1 mIU/l, assay manufacturer: Diasorin), * baseline (pre-DXM) Ald\<3 ng/dl, * overt clinical and/or biochemical features of adrenal hormone deficiency or excess other than MACS (8 a.m. cortisolemia in the 50-140 nmol/l range in the 1-mg DXM test), * therapy with glucocorticoids, non-steroidal anti-inflammatory drugs, hormonal replacement therapy, hormonal contraceptive therapy, and/or licorice intake, * established or suspected secondary HT other than due to PA, * comorbidities including: poorly controlled and/or other than type 2 diabetes mellitus (T2DM), present and past alcohol abuse, obesity grade 3 (i.e. body mass index of at least 40 kg/m2), severe CV disease disqualifying a patient from chronic medication modification, active malignancy, decompensated autoimmune disease as well as an autoimmune disease associated with cardiovascular and/or renal complications, estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2, poor physical condition, lack and withdrawal of consent for participation.

Dietary Salicylates and Preeclampsia

NCT06239363
Recruiting
Conditions Pregnancy Disease, Preeclampsia, Diet Ha...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Preeclampsia (PE) is an important pregnancy complication and cause of maternal and perinatal mortality and morbidity. The underlying etiology and pathophysiology of preeclampsia is incompletely understood but it involves dysfunctional cytotrophoblastic invasion, placental ischemia, and release of inflammatory and endothelial mediators. Placenta dysfunction in PE is related to angiogenic balance. Currently, therapeutic options for the prevention and treatment of PE are limited. It is known that the risk of PE is reduced by low-dose aspirin. Therefore, the influence of salicylates on the development of PE seems to need to be investigated. This project plans to examine the preventive effects of food sources of salicylic acid and compare their effects with aspirin. Therefore, the aim of the present study is thus answer the following questions. whether the maternal dietary intake of salicylates is related to placental angiogenesis; 2. whether naturally occurring salicylates have the same effects on preeclampsia development and placental angiogenesis as aspirin. To answer these questions we plan to carry out a human study with pregnant women. Due to the above the planned research aims to determine the association between maternal dietary intake of salicylates and placental angiogenesis and the risk of preeclampsia development. Although PE remains an incurable disease, the results of this project will enable the development of dietary recommendations for the prevention and treatment of preeclampsia. Moreover, the results of this study may be useful in lowering the cost of maternal and fetal complications from preeclampsia and the cost of their hospitalization.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • daily intake using 24-hour Dietary Recall (3 years)
  • salicylates (3 years)
  • angiogenesis biomarker: sFLT1 (3 years)
  • angiogenesis biomarker: VEGF (3 years)
  • angiogenesis biomarker: PLGF (3 years)
  • STOX-1 protein (3 years)
  • inflammatory biomarker: TNFα (3 years)
  • inflammatory biomarker: hsCRP (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-08
Completion: 2028-09-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Poznan University of Life Sciences
Contact Information
Study Contact:
Joanna Suliburska, Professor
+48 61 8487260
joanna.suliburska@up.poznan.pl
Joanna Suliburska, Professor
+48 618487260
joanna.suliburska@up.poznan.pl
Poznan University of Life Sciences
Interventions
N/A
Study Locations (1 sites)
Poznan University of Life Sciences, Poznan, 60-624 Poland
Eligibility Criteria
Inclusion Criteria: * age 18-45 years * healthy women with no previous adverse medical history and women with diagnosed preeclampsia * singleton pregnancy * people who have the full ability to give informed consent. Exclusion Criteria: * pregnancies with detectable fetal defects, chromosomal abnormalities, genetic syndromes * infections * history of chronic hypertension, metabolic disorder before or during pregnancy, or the presence of high-risk factors such as heart diseases, diabetes, and renal diseases.
Conditions Chronic Thromboembolic Pulmonary Hyperte...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to gather information on background, medical history, symptoms and physical condition, treatment options of people with chronic thromboembolic pulmonary hypertension in real clinical practice in Russia. The main question it aims to answer is: Which factors most influence the prognosis of participants?

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Procedure: Pulmonary endarterectomy — A surgical procedure to remove chronic blood clots from the pulmonary arteries
  • Procedure: Balloon pulmonary angioplasty — A minimally invasive procedure used to treat chronic thromboembolic pulmonary hypertension by dilatating narrowed pulmonary arteries and improving blood flow to the lungs
  • Drug: Pulmonary hypertension-specific therapy — Medical treatment with any PH-specific drugs

Primary Outcomes

  • All-cause mortality (Up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-01
Completion: 2035-05-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Irina E. Chazova
Contact Information
Study Contact:
Galina V Schelkova
+74954146270
GVShchelkova@Cardio.ru
National Medical Research Center of Cardiology after academician E.I. Chazov
Irina E Chazova, D. Sci. (Med.)
National Medical Research Center of Cardiology after academician E.I. Chazov
Nikolay M Danilov, D. Sci. (Med.)
National Medical Research Center of Cardiology after academician E.I. Chazov
Interventions
  • Procedure: Pulmonary endarterectomy — A surgical procedure to remove chronic blood clots from the pulmonary arteries
  • Procedure: Balloon pulmonary angioplasty — A minimally invasive procedure used to treat chronic thromboembolic pulmonary hypertension by dilatating narrowed pulmonary arteries and improving blood flow to the lungs
  • Drug: Pulmonary hypertension-specific therapy — Medical treatment with any PH-specific drugs
Study Locations (1 sites)
National Medical Research Center of Cardiology after academician E.I. Chazov, Moscow, Russia
Eligibility Criteria
Inclusion Criteria: * Presence of a confirmed diagnosis of CTEPH Exclusion Criteria: * Presence of pulmonary hypertension of a different etiology than CTEPH